FTRE

Fortrea (FTRE), a leading global CRO, announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026, with a fireside chat and 1x1 meetings scheduled.

Fortrea Holdings Inc. (FTRE) is expected to report Q3 2026 earnings of $0.24 per share, representing 100% year-over-year growth, though revenues are projected to decline 4.4%. With a negative Earnings ESP of -10.35% and Zacks Rank #3 (Hold), the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in 2 of the last 4 quarters.

Vertex Pharmaceuticals is expected to report Q3 2026 earnings of $4.92 per share (up 2.5% YoY) with revenues of $3.4 billion (up 10.6% YoY) on November 2. The company has a positive Earnings ESP of +4.98% combined with a Zacks Rank #3, suggesting a likely earnings beat. However, past performance shows mixed results with only 2 beats in the last 4 quarters.

Fortrea, a leading Contract Research Organization (CRO), has partnered with Omico, Australia's precision oncology screening platform, to accelerate biomarker-driven cancer clinical trials in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial planning, site selection, and patient recruitment, leveraging Omico's database of over 23,000 consented patients and referrals from 1,600+ clinicians across Australia.

Fortrea, a leading clinical research organization, has partnered with Omico, Australia's precision oncology testing and clinical trial matching organization, to accelerate biomarker-based cancer research in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve patient-trial matching, enhance site selection efficiency, and expand access to precision oncology research globally.

Fortrea, a leading global contract research organization, has partnered with Omico, Australia's precision oncology leader, to accelerate biomarker-driven cancer research. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial site selection, patient recruitment, and access to biomarker-matched trials in Australia, leveraging Omico's database of over 23,000 consented patients and 1,600+ referring physicians.

Fortrea, a leading clinical development CRO, has partnered with Omico, Australia's precision oncology screening organization, to accelerate biomarker-driven cancer clinical trials. The collaboration combines Fortrea's oncology trial expertise with Omico's PrOSPeCT platform to improve trial site selection, patient matching, and recruitment efficiency in Australia, with plans to expand globally.

Fortrea, a leading global clinical research organization, has partnered with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven cancer drug development. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve study planning, patient recruitment, and access to biomarker-based clinical trials in Australia, leveraging Omico's database of over 23,000 patients and referrals from 1,600+ Australian physicians.

Fortrea, a leading global contract research organization, has announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology drug development. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial planning, site selection, and patient recruitment for targeted cancer therapies in Australia.